NewAmsterdam Pharma to Attend Investor Conferences Scheduled for December

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 25 2025

0mins

Source: Globenewswire

Company Overview: NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL cholesterol, aiming to address unmet needs in LDL-lowering therapies.
Upcoming Conferences: The company will participate in several investor conferences, including the Evercore Healthcare Conference on December 2, Citi’s Global Healthcare Conference on December 3, and the Piper Sandler Healthcare Conference on December 4, 2025.
Fireside Chats: Key executives, including CEO Michael Davidson and CFO Ian Somaiya, will engage in fireside chats at these conferences, with live webcasts available on the company's investor relations website.
Product Development: NewAmsterdam is conducting multiple phase 3 trials for obicetrapib, a CETP inhibitor, as a potential LDL-C lowering therapy, either alone or in combination with ezetimibe, for patients who do not respond well to existing treatments.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free